SP
BravenNow
Form 13G Alkermes PLC For: 26 March
| USA | economy | ✓ Verified - investing.com

Form 13G Alkermes PLC For: 26 March

#Form 13G #Alkermes PLC #SEC filing #beneficial ownership #institutional investor #March 26 #passive investment

📌 Key Takeaways

  • A Form 13G was filed for Alkermes PLC on March 26, indicating a significant passive investment.
  • The filing reveals a major shareholder or institutional investor has taken a substantial position in the company.
  • This disclosure is required by the SEC for beneficial ownership exceeding 5% of a company's stock.
  • The filing date suggests the investment position was established or reported as of that specific date.

🏷️ Themes

SEC Filing, Investment

📚 Related People & Topics

SEC filing

SEC filing

Type of financial statements in the United States

# SEC Filing An **SEC filing** is a formal financial statement or regulatory document submitted to the **U.S. Securities and Exchange Commission (SEC)**. These filings are mandatory requirements designed to ensure transparency, providing a standardized method for disclosing material information to ...

View Profile → Wikipedia ↗

Entity Intersection Graph

Connections for SEC filing:

🌐 Insider trading 13 shared
👤 New York Stock Exchange 5 shared
🌐 Restricted stock 5 shared
🌐 SEC 4 shared
🌐 Nasdaq 3 shared
View full profile

Mentioned Entities

SEC filing

SEC filing

Type of financial statements in the United States

Deep Analysis

Why It Matters

This Form 13G filing reveals significant institutional ownership in Alkermes PLC, a biopharmaceutical company focused on central nervous system diseases and oncology. This matters because large institutional investments signal confidence in the company's pipeline and financial stability, potentially influencing stock prices and investor sentiment. The disclosure affects shareholders, potential investors, and market analysts who track institutional movements to gauge market trends. It also provides transparency about who holds substantial voting power in the company, which can impact corporate governance decisions.

Context & Background

  • Form 13G is an SEC filing required when an institutional investor acquires 5% or more of a company's outstanding shares, indicating passive investment intent rather than active control-seeking.
  • Alkermes PLC is an Irish-domiciled biopharmaceutical company that develops medicines for conditions like schizophrenia, depression, addiction, and multiple sclerosis, with products including Aristada and Vivitrol.
  • Institutional ownership filings like 13G are closely monitored by market participants as they can signal institutional confidence or lack thereof in a company's future prospects.
  • Previous 13G filings for Alkermes have shown varying levels of institutional interest, often correlating with clinical trial results or FDA approval announcements for their drug pipeline.

What Happens Next

Market analysts will review the filing details to identify the specific institutional investor(s) involved and their investment history. The disclosure may lead to increased trading volume in Alkermes shares as other investors react to the institutional position. Future SEC filings will be monitored to see if the position increases, decreases, or converts to a more active Form 13D, which would indicate an intent to influence company management.

Frequently Asked Questions

What is the difference between Form 13G and Form 13D?

Form 13G is for passive investors who acquire 5%+ ownership without intent to influence control, while Form 13D is for active investors seeking to influence management or pursue strategic changes. 13G requires less detailed disclosure and has shorter filing deadlines after acquisition.

Why would an institutional investor file a 13G for Alkermes?

Institutional investors typically file 13G when they believe Alkermes represents a valuable long-term investment based on its drug pipeline, financial performance, or market position. This often reflects confidence in the company's research and development capabilities in neuroscience and oncology treatments.

How does this filing affect ordinary Alkermes shareholders?

Ordinary shareholders may see increased stock volatility following the disclosure, but substantial institutional ownership generally provides stability and liquidity. The filing also reveals voting power concentration, which could influence future shareholder proposals or board elections.

What specific information does Form 13G disclose about the investment?

Form 13G discloses the investor's identity, number of shares owned, percentage of outstanding shares, acquisition date, and investment purpose (passive). It also shows share types (common vs. preferred) and any shared voting or dispositive power arrangements.

}

Source

investing.com

More from USA

News from Other Countries

🇬🇧 United Kingdom

🇺🇦 Ukraine